Pilot studies: one swallow does not make a summer...

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Netherlands Journal of Medicine

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 14692438
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of granisetron, a 5-HT3 receptor antagonist, in the treatment of chronic fatigue syndrome patients--a pilot study.

  2003cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis

  2003cited by this paper
• Increasing the Efficacy of Anti-Inflammatory Agents Used in the Treatment of Sepsis

  2003cited by this paper
• Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

  2003cited by this paper
• Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis.

  2002cited by this paper
• Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alfa for Crohn's disease

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red.

  1999cited by this paper
• Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red.

  1999cited by this paper
• An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock

  1999cited by this paper
• Nitric oxide synthase inhibitors--a mechanism-based treatment of septic shock.

  1999cited by this paper
• An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.

  1999cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

  1997cited by this paper
• Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

  1995cited by this paper
• A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis.

  1995cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

  1994cited by this paper
• Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice.

  1993cited by this paper
• Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine

  1990cited by this paper
• Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study.

  1989cited by this paper

• Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial.

  2018cites this paper